From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.
about
Rebuilding cancer metastasis in the mouseSchisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transitionThe transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesisMarine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.Breast cancer cell adhesome and degradome interact to drive metastasisAn improved syngeneic orthotopic murine model of human breast cancer progressionMouse models of breast cancer metastasis.Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in micePathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.Genetically engineered mice as experimental tools to dissect the critical events in breast cancerEstablishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea.Hydrodynamic cell delivery for simultaneous establishment of tumor growth in mouse lung, liver and kidneyMouse models of advanced spontaneous metastasis for experimental therapeutics.Animal models for exploring the pharmacokinetics of breast cancer therapiesLoss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivoNovel mouse mammary cell lines for in vivo bioluminescence imaging (BLI) of bone metastasis.Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden.Is tail vein injection a relevant breast cancer lung metastasis model?Near-infrared bioluminescent proteins for two-color multimodal imaging.An improved model to study tumor cell autonomous metastasis programs using MTLn3 cells and the Rag2(-/-) gammac (-/-) mouse.Combination approaches to immunotherapy: the radiotherapy example.Animal models for breast cancer metastasis to bone: opportunities and limitations.Loss of Caveolin-1 in Metastasis-Associated Macrophages Drives Lung Metastatic Growth through Increased Angiogenesis.Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/Neu transgenic mice.Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation.
P2860
Q26864450-1C6E6B9C-1B5F-43C0-BD2B-1F895B91D8C4Q27334832-1821FFCD-5A49-42EB-AB95-A58407A217B9Q33371124-E8CEA6B7-C5AF-43C7-899D-6D35BEFE334DQ33834080-171E3CBE-15A0-4145-A2B7-624C6465C92CQ33914711-361F9AD2-4A5B-4601-AD6C-212AA8333BB4Q34250295-334FE05E-64FD-40EA-BB19-137328D0AC05Q34553964-194F7DDC-D216-4232-918C-402D6C323A1DQ34613492-36D427BA-0892-4C25-8AA9-94DBE3A55B38Q34990925-729C56B7-793B-4A32-B1C3-94E46FDB93BAQ35010102-FBF84CF5-6BC2-41E7-8AF1-D2CB92CADD93Q35146602-7A2BA110-2058-4E3C-B9D4-C2F9AF458C58Q35256614-427645D1-62B3-4F8E-A3A1-CEC5742B53E4Q35556784-A10F80CE-7BC9-42BD-BF2D-2828A9E408C5Q35966786-C99F8196-D8B2-4DED-9192-8BDCB4ACD37CQ36093956-CF6D23B2-EAB6-4AD3-B9C1-E7150DDCF30BQ36245406-81076619-BED5-4B61-9797-6F632B6DA2E2Q36323486-39B7BAF8-D79F-498C-95CE-5BEFBBD874D8Q36875703-07CF5054-6BD6-4219-BA25-B63AFA170284Q37127936-821E68E5-E7AC-4132-8DAA-5EB1A36E81CAQ37408533-1D54737A-7CEA-47BF-8147-F4C86134A7D5Q37418688-D9917F16-4541-4D25-9A81-4108544C704DQ37773250-6184BBD8-884D-43A8-9A64-410765E90DDCQ38573510-13161FEF-F357-42E1-ADEA-D68547B9B774Q47147967-2EE7FFA7-BFF8-4872-BDCC-EE4DF6AE3A5EQ51332682-7B46E454-1B65-47D6-A0D2-DD8E7CEC450BQ53418683-99E4DC53-4ECE-48E2-8887-93697F118D0B
P2860
From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
From genetic abnormality to me ...... pment of anticancer therapies.
@ast
From genetic abnormality to me ...... pment of anticancer therapies.
@en
type
label
From genetic abnormality to me ...... pment of anticancer therapies.
@ast
From genetic abnormality to me ...... pment of anticancer therapies.
@en
prefLabel
From genetic abnormality to me ...... pment of anticancer therapies.
@ast
From genetic abnormality to me ...... pment of anticancer therapies.
@en
P2093
P2860
P1476
From genetic abnormality to me ...... pment of anticancer therapies.
@en
P2093
P2860
P2888
P304
P356
10.1007/S10549-005-9067-X
P407
P577
2006-03-01T00:00:00Z